
Charles J Eyermann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11934905/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	X-ray Crystal Structures of <i>Escherichia coli</i> RNA Polymerase with Switch Region Binding Inhibitors Enable Rational Design of Squaramides with an Improved Fraction Unbound to Human Plasma Protein. Journal of Medicinal Chemistry, 2015, 58, 3156-3171.	6.4	36
2	Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa. Bioorganic and Medicinal Chemistry, 2014, 22, 5392-5409.	3.0	26
3	Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II: Broad-Spectrum Antibacterial Agents with Reduced hERG Activity. Journal of Medicinal Chemistry, 2011, 54, 7834-7847.	6.4	101
4	Novel Substituted (Pyridin-3-yl)phenyloxazolidinones:  Antibacterial Agents with Reduced Activity against Monoamine Oxidase A and Increased Solubility. Journal of Medicinal Chemistry, 2007, 50, 4868-4881.	6.4	38
5	Identification of 4-Substituted 1,2,3-Triazoles as Novel Oxazolidinone Antibacterial Agents with Reduced Activity against Monoamine Oxidase A. Journal of Medicinal Chemistry, 2005, 48, 499-506.	6.4	282
6	Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain: Phosphotyrosine mimetics exploiting multifunctional group replacement chemistry*. Biopolymers, 2003, 71, 717-729.	2.4	16
7	Src Homology-2 Inhibitors: Peptidomimetic and Nonpeptide. Mini-Reviews in Medicinal Chemistry, 2002, 2, 475-488.	2.4	58
8	A novel phosphotyrosine mimetic 4′-carboxymethyloxy-3′-phosphonophenylalanine (cpp): exploitation in the design of nonpeptide inhibitors of pp60Src SH2 domain. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2319-2323.	2.2	28
9	Nonpeptide Cyclic Cyanoguanidines as HIV-1 Protease Inhibitors:Â Synthesis, Structureâ^'Activity Relationships, and X-ray Crystal Structure Studies. Journal of Medicinal Chemistry, 1998, 41, 1446-1455.	6.4	55
10	Calculated and Experimental Low-Energy Conformations of Cyclic Urea HIV Protease Inhibitors. Journal of the American Chemical Society, 1998, 120, 4570-4581.	13.7	48
11	Molecular Recognition of Cyclic Urea HIV-1 Protease Inhibitors. Journal of Biological Chemistry, 1998, 273, 12325-12331.	3.4	40
12	The role of computer-aided and structure-based design techniques in the discovery and optimization of cyclic urea inhibitors of hiv protease. Advances in Amino Acid Mimetics and Peptidomimetics, 1997, , 1-40.	0.3	8
13	Cyclic HIV Protease Inhibitors: Synthesis, Conformational Analysis, P2/P2â€~ Structureâ^'Activity Relationship, and Molecular Recognition of Cyclic Ureas. Journal of Medicinal Chemistry, 1996, 39, 3514-3525.	6.4	182
14	Design, synthesis and in vitro activities of a series of benzimidazole/benzoxazole glycoprotein IIb/IIIa inhibitors. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 339-344.	2.2	24
15	Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chemistry and Biology, 1996, 3, 301-314.	6.0	136
16	NMR and X-ray Evidence That the HIV Protease Catalytic Aspartyl Groups Are Protonated in the Complex Formed by the Protease and a Non-Peptide Cyclic Urea-Based Inhibitor. Journal of the American Chemical Society, 1994, 116, 10791-10792.	13.7	127
17	NMR Evidence for the Displacement of a Conserved Interior Water Molecule in HIV Protease by a Non-Peptide Cyclic Urea-Based Inhibitor. Journal of the American Chemical Society, 1994, 116, 1581-1582.	13.7	61
18	Structural Studies of a Family of High Affinity Ligands for GPIIb/IIIa. Journal of the American Chemical Society, 1994, 116, 3207-3219.	13.7	130